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205(St. Jude Medical) was applied with an intracoronary bolus
administration of adenosine (80 mg in the left coronary artery and
40 mg in the right coronary artery) to induce maximal hyperemia.
The jailed side branch was considered functionally signiﬁcant when
the FFR was #0.8.
Initially, 90 patients with 90 lesions were studied. However,
8 lesions were excluded due to poor quality of the recon-
structed 3D OCT images. Therefore, 82 lesions in 82 patients
were ﬁnally included in this study. A functionally signiﬁcant
stenosis was observed in 20 (24.4%) jailed side branches. Using
receiver-operating characteristic curve analysis, the best cutoff
value of the 3D OCT reconstructed side-branch MLA was
2.05 mm2 for predicting a functionally signiﬁcant stenosis (area
under the curve: 0.81, 95% conﬁdence interval: 0.71 to 0.91;
p < 0.001; sensitivity: 71.0%; speciﬁcity 75.0%; positive pre-
dictive value: 54.5%; negative predictive value: 91.5%) (Figs. 1E
and 1F).
In conclusion, 3D OCT had a modest ability to predict the
functional signiﬁcance for borderline lesions caused by a jailed side-
branch ostium.
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Guest Editor for this paper.Table 1. Distribution of Demographic, Clinical, and Functional Parameters Am
Type 1
(n [ 71
[13.7%])
Type 2
(n [ 232
[44.6%])
T
(n [
[33
Age <45 yrs 54 (76.0) 135 (58.2) 10
Female 46 (64.8) 168 (72.4) 11
Hypertension 24 (33.8) 90 (38.8) 3
CoA 23 (32.3) 58 (25.0) 6
Curtain shunt 28 (39.4) 123 (53.0) 10
Permanent shunt 25 (35.2) 117 (50.4) 13
Recurrent CIE 34 (47.8) 138 (59.4) 12
Multiple CIF RMi 30 (42.2) 121 (52.1) 11
Values are n (%).
CIE ¼ cerebral ischemic event; CIF ¼ cerebral ischemic foci; CoA ¼ coagulation abnormalities (
trahydrofolate reductase or antiphospholipid or anticardiolipin antibodies); RMi ¼ resonance magICE-Classiﬁcation of Interatrial
Septum Anatomy in Patients
With R/L Shunt
Right-to-left (R-to-L) shunt caused by patent foramen ovale (PFO)
is a dark ﬁeld for interventionalists, particularly after the conﬂicting
results from the most recent trials regarding PFO transcatheter
closure. It seems that the confusing results (negative in the Closure I
[Closure or Medical Therapy for Cryptogenic Stroke With Patent
Foramen Ovale] trial [1] and slightly positive in the RESPECT
[Randomized Evaluation of Recurrent Stroke Comparing PFO
Closure to Established Current Standard of Care Treatment] and
PC [Percutaneous Closure of Patent Foramen Ovale in Cryptogenic
Embolism] [2,3] trials) might be related to patient selection, in
particular anatomical inclusion/exclusion criteria and device choice.
We tried to clarify the relationships of different anatomical subtypes
and the association of anatomical characteristics of the interatrial
septum with risk of recurrent paradoxical embolism and shunt
grade.
We retrospectively reviewed the medical and instrumental data of
520 consecutive patients (mean age 44.0  15. 5 years; 355 females)
who had been referred to our center over a 10-year period (February
2003 to February 2013) for R-to-L shunt catheter-based closure.
Inclusion criteria for percutaneous closure of PFO included the
following: 1) a concurrent permanent or shower or curtain shunt
pattern on transcranial Doppler with Valsalva maneuver; 2) positive
(single or multiple ischemic foci) cerebral magnetic resonance im-
aging; 3) previous neurologically conﬁrmed stroke or transient
ischemic attack; and 4) moderate or large PFO on transesophageal
echocardiography. The hospital ethical board approved the study,
and written informed consent was obtained from all patients enrolled
in the study.
In all patients, the attempt at transcatheter closure was preceded
by a mechanical 9-F, 9-MHz, 360 scan probe (UltraICE, EP
Technologies, Boston Scientiﬁc Corporation, San Jose, California)
intracardiac echocardiography. This study was conducted in 2 pro-
jections, measuring diameters of the oval fossa, the entire atrialong the 4 Anatomical Subtypes
ype 3
175
.6%])
Type 4
(n [ 42
[8.1%]) p Value
Total
(N [ 520)
2 (58.3) 21 (50.0) <0.0001 312 (61.7)
9 (68.0) 22 (55.5) 0.0752 355 (68.3)
6 (20.5) 6 (14.3) <0.0001 156 (30.0)
6 (37.7) 14 (33.3) 0.0955 162 (31.1)
8 (61.7) 30 (71.4) 0.0068 289 (55.6)
8 (78.8) 21 (50.0) <0.0001 301 (57.8)
8 (73.1) 21 (50.0) <0.0001 321 (61.7)
8 (67.4) 28 (66.6) <0.0001 297 (57.1)
deﬁciency of anti-thrombin III, C, S, or factor V Leiden or homozygotic mutation methylenete-
netic imaging.
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206septum length, and rims and thickness with electronic caliper edge-
to-edge (4). Four main features were used to analyze patients: 1)
diameter of the fossa ovalis (FO); 2) presence and length of the
channel; 3) presence and degree of atrial septal aneurysm (ASA),
following the classiﬁcation of Olivares et al. (5); and 4) rim thick-
ness. We also analyzed the presence of Eustachian valve and Chiari’s
network. We considered eventual additional fenestrations within the
fossa as a functional subtype of PFO, despite that, anatomically,
they should be considered as secundum atrial septal defects.
Thus, combinations of interatrial septum anatomical features
were classiﬁed into 4 main anatomical subgroups: type 1, small
FO, no ASA, short channel, normal rims; type 2, small FO, no
ASA, long channel, normal or hypertrophic rims; type 3, large
FO, 4 to 5 ASA, short channel, normal or hypertrophic rims; and
type 4, large FO, 3 to 5 ASA, multifenestrated, short channel,
normal rims (Table 1).
FO diameter #20 mm was found to be statistically correlated
to the presence of a tunnelized PFO (r ¼ 0.91, p < 0.001),
whereas FO diameter >25 mm was associated with the presence
of ASA (r ¼ 0.88, p < 0.001) and a linear correlation between
diameter of the FO and ASA severity (the larger the fossa, the
more severe the ASA) (r ¼ 0.90, p < 0.001). Type 3 anatomical
subtype (odds ratio: 4.1 [95% conﬁdence interval: 1.5 to 8.0];
p < 0.001) and type 2 þ Eustachian valve (odds ratio: 4.3 [95%
conﬁdence interval: 1.6 to 9.0]; p < 0.001) were the strongest
predictors of recurrent ischemic events before transcatheter
closure.
Our study suggests that the anatomy of the interatrial septum
associated with R-to-L shunt is more complex than commonly
thought. The combination of the varieties of such anatomical
components identifying 4 main anatomic subtypes may help in
better clarifying the pathophysiology of paradoxical embolism,
which is unlikely to be dominated by 1 factor only, such as
ASA, PFO tunnel, or fenestrations. Intriguingly, our data
suggest that the FO diameter plays a role in determining the
presence of both tunnelized PFO, when the oval fossa is small
(<20 mm), and the presence of aneurysm, when the fossa is
large ($20 mm).
In conclusion, our study showed that in a “real-world” interatrial
septum, anatomy greatly differs among patients with R-to-L shunt.
The clinical signiﬁcance of each anatomical pattern seems different:
a device closure might be advisable in patients with high-risk
anatomical patterns whereas a medical strategy might be adopted
in the others.
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Perﬂutren-Based Echocardiographic
Contrast in Patients With
Right-to-Left Intracardiac Shunts
Use of second-generation perﬂutren-based echocardiographic
contrast agents (perﬂutren) is currently contraindicated in
patients with known right-to-left, bidirectional, or transient right-
to-left intracardiac shunts (intracardiac shunts) according to the
U.S. Food and Drug Administration. This contraindication
is primarily a result of concerns related to neurological complications
and/or systemic embolism from animal data describing entrapment
of perﬂutren lipid microspheres (>5 mm in diameter) within small
arterioles and capillaries in skeletal muscles after intra-arterial in-
jection. To date, no deﬁnitive evidence demonstrates patient safety
concerns from perﬂutren use in humans with intracardiac shunts.
We sought to evaluate the association between perﬂutren use and
adverse events in these patients.
A retrospective cohort study was performed to evaluate the as-
sociation of perﬂutren use (Deﬁnity, Lantheus Medical Imaging,
North Billerica, Massachusetts; Optison, GE Healthcare, Milwau-
kee, Wisconsin) and adverse events in patients with and without
known intracardiac shunts using the echocardiography database at
Hennepin County Medical Center (Minneapolis, Minnesota). The
study was approved by the institutional review board. Patients with
known intracardiac shunts (diagnosed using right heart contrast
[agitated saline/50% dextrose] or color ﬂow Doppler) were identi-
ﬁed from the database. Per laboratory protocol, perﬂutren was not
used in patients with cyanotic congenital heart disease. Documen-
tation of all adverse events reported by laboratory personnel within a
30-min interval after perﬂutren administration was identiﬁed. In-
dividual patient charts were reviewed to conﬁrm clinical events in all
patients who experienced adverse events. All adverse events were
further categorized as primary or secondary. Primary events were
deﬁned as neurological (stroke/transient ischemic attack) and/
or systemic embolism. Secondary events, collectively referred to
as complement activation-related pseudoallergy (CARPA), included
angioedema, bronchospasm, hypotension, hypoxemia, low back
pain, and urticaria. Fisher exact test was used to evaluate statistical
signiﬁcance.
From February 1, 1998, through November 30, 2012, 39,020
echocardiograms were performed using perﬂutren (Deﬁnity:
34,598; Optison: 4,422). An intracardiac shunt was not identiﬁed
